Projects
DonoR-specific antilbodiES in cryo-bioPsIes and bRonchoAlveolar lavage fluid during rejecTIOn after luNg transplantation [Acronym: RESPIRATION] KU Leuven
Transcriptome-based management of transplant-related pulmonary fibrosis in chronic pulmonary rejection after lung or allogeneic stem cell transplantation KU Leuven
Background Chronic lung allograft dysfunction (CLAD) and chronic pulmonary graft versus host disease (cGvHD) are life-threatening conditions commonly encountered after lung transplantation and allogeneic hematopoietic stem cell transplantation. Pathophysiological and molecular pathways associated with transplant-related pulmonary fibrosis leading to structural changes and lung failure in CLAD pulmonary cGvHD remain unknown. Aims The primary ...
Physical activity in patients with respiratory disease and lung transplantation. KU Leuven
Risk factors and phenotypes of chronic rejection after lung transplantation. KU Leuven
Translational research on chronic rejection after lung transplantation: Restrictive Allograft Syndrome after lung transplantation: exploring pathophysiological mechanisms and targeted therapy KU Leuven
Translational research on chronic rejection after lung transplantation: towards better treatment in patients. KU Leuven
My BOF−ZAP project is part of the BREATHE research group and includes research into rejection after lung transplantation focusing on structural changes of the lung and the allo-immune response. This research ranges from basic experimental research in cell cultures and laboratory animals to translation to the human lung and the patient. The final objective remains to increase the quality and survival of the lung transplant patient. We aim to ...
Novel strategies to increase the number and quality of donor lungs for transplantation KU Leuven
Lung transplantation is a lifesaving treatment option in well-selected patient with end-stage lung disease. Due to the successes of lung transplantation, transplant programs are expanding rapidly worldwide. However, two major problems impede optimal outcome early after lung transplantation. First, 10 to 30% of all lung recipients develop primary graft dysfunction, which is the leading cause of early morbidity and mortality after lung ...
Assessment and management of donor lungs for transplantation KU Leuven
Lung transplantation (Ltx) is the only life-saving treatment for selected patients with end-stage pulmonary disease. Donor organ shortage and primary graft dysfunction (due to ischemia-reperfusion injury) are two major obstacles in the early stages of LTX that might limit the outcome. Therefeore, optimization of donor organ quality and expansion of the donor pool are crucial.
The first objective of this research proposal is to ...